2. Search Result
Search Result
Results for "

Auristatin F-d<sub>8</sub>

" in MedChemExpress (MCE) Product Catalog:

3960

Inhibitors & Agonists

1

Screening Libraries

12

Fluorescent Dye

14

Biochemical Assay Reagents

9

Peptides

13

Inhibitory Antibodies

19

Natural
Products

11

Recombinant Proteins

3753

Isotope-Labeled Compounds

6

Antibodies

21

Click Chemistry

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F-d8
  • HY-12522S
    PF-06380101-d8
    2 Publications Verification

    Aur0101-d<sub>8sub>; Auristatin-0101-d<sub>8sub>

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    PF-06380101-d8 is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue .
    PF-06380101-d8
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E-d8
  • HY-13631AS
    Exatecan-d5 mesylate

    DX8951f-d<sub>5sub>; Deuterated labeled Exatecan mesylate

    		 Isotope-Labeled Compounds ADC Cytotoxin Topoisomerase Cancer
    Exatecan-d5 (DX8951f-d5) mesylate is deuterium labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research .
    Exatecan-d5 mesylate
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E TFA
  • HY-W706161
    Kresoxim-methyl-d7

    BAS 490 F-d<sub>7sub>

    		 Isotope-Labeled Compounds Others
    Kresoxim-methyl-d7 (BAS 490 F-d7) is deuterium labeled Kresoxim-methyl .
    Kresoxim-methyl-d7
  • HY-13631AS1
    Exatecan-d3 mesylate

    DX8951f-d<sub>3sub> mesylate

    		 Topoisomerase Isotope-Labeled Compounds ADC Cytotoxin Cancer
    Exatecan-d3 (DX8951f-d3) mesylate is deuterium-labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL .
    Exatecan-d3 mesylate
  • HY-162068
    Auristatin23

    		Drug Derivative Cancer
    Auristatin23, a conjugate of Auristatin F (HY-15583), is a cytotoxin. Auristatin23 exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ .
    Auristatin23
  • HY-145989
    Aminobenzenesulfonic auristatin E

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic auristatin E
  • HY-15582G
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .
    Auristatin E
  • HY-RS13999
    SUB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-RS18793
    Sub1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sub1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sub1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sub1 Mouse Pre-designed siRNA Set A
    Sub1 Mouse Pre-designed siRNA Set A
  • HY-RS25282
    Sub1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sub1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sub1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sub1 Rat Pre-designed siRNA Set A
    Sub1 Rat Pre-designed siRNA Set A
  • HY-146227
    DNA topoisomerase II inhibitor 1

    		Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
    DNA topoisomerase II inhibitor 1
  • HY-14648S5
    Dexamethasone-d3-1

    Hexadecadrol-d<sub>3sub>-1; Prednisolone F-d<sub>3sub>-1

    		 Isotope-Labeled Compounds Antibiotic Autophagy Glucocorticoid Receptor SARS-CoV ADC Cytotoxin Mitophagy Complement System Bacterial Cancer
    Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d3-1
  • HY-133852
    FD-1080

    		Fluorescent Dye Others
    FD-1080 is a fluorophore with both excitation and emission in the NIR-II region (Ex=1064 nm, Em=1080 nm). FD-1080 can be used for in vivo imaging .
    FD-1080
  • HY-133852A
    FD-1080 free acid
    1 Publications Verification

    		 Fluorescent Dye Others
    FD-1080 free acid is a fluorophore with both excitation and emission in the NIR-II region (Ex=1064 nm, Em=1080 nm). FD-1080 free acid can be used for in vivo imaging .
    FD-1080 free acid
  • HY-N8409
    FD-838

    		Others Others
    FD-838 is a Alkaloids product that can be isolated from the mycelia of the basidiomycete Hericium erinaceum. .
    FD-838
  • HY-15575S
    VcMMAE-d8

    MC-Val-Cit-PAB-MMAE-d<sub>8sub>; mc-vc-PAB-MMAE-d<sub>8sub>

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
    VcMMAE-d8
  • HY-D2294
    FD dye 7

    		Fluorescent Dye Others
    FD dye 7 (compound 7) is an intermediate of heptamethacyanine dye fluorescent dye and can be used to synthesize dyes FD-1 and FD-2 .
    FD dye 7
  • HY-128570
    FD-IN-1

    		Complement System Inflammation/Immunology
    FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
    FD-IN-1
  • HY-148171
    L-2'-Fd4C

    		HIV HBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection
    L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity .
    L-2'-Fd4C
  • HY-155529
    FD1024

    		Pim Cancer
    FD1024 is PIM inhibitor (IC50s: 1.96, 38.9, 4.17 nM for PIM1, 2, 3). FD1024 can be used for research of acute myeloid leukemia. FD1024 has strong antiproliferative activity against the tested AML cell lines, with 0.16 μM, 0.12 μM, 1.05 μM, 1.39μM for EOL-1, MV-4-11, KG-1, MOLM-16 cells. FD1024 also has antitumor efficacy in mice .
    FD1024
  • HY-132231
    FD223

    		PI3K Apoptosis Cancer
    FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML .
    FD223
  • HY-155066
    FD274

    		PI3K mTOR Cancer
    FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .
    FD274
  • HY-114461B
    (3S,17S)-FD-895

    		Drug Metabolite Cancer
    (3S,17S)-FD-895 is a FD-895 analogue. (3S,17S)-FD-895 can inhibit the growth of HCT116 cells and has splicing regulation activity. (3S,17S)-FD-895 can be used in the study of cancer .
    (3S,17S)-FD-895
  • HY-15583
    Auristatin F

    		ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F
  • HY-10844S1
    Pretomanid-d5

    PA-824-d<sub>5sub>; (S)-PA 824-d<sub>5sub>

    		 Antibiotic Bacterial Isotope-Labeled Compounds Infection Cancer
    Pretomanid-d5 is deuterated labeled Pretomanid (HY-10844). Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid-d5
  • HY-15162A
    MMAE-d8
    5+ Cited Publications

    Monomethyl Auristatin E-d<sub>8sub>; Deuterated labeled MMAE

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d8
  • HY-134178S1
    5-Fluorouridine 5'-triphosphate-13C,19F,d1

    		Isotope-Labeled Compounds Others
    5-Fluorouridine 5'-triphosphate- 13C, 19F,d1 is deuterium and 13C-labeled 5-Fluorouridine 5'-triphosphate (HY-134178).
    5-Fluorouridine 5'-triphosphate-13C,19F,d1
  • HY-155180
    FD2056

    		PI3K Cancer
    FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC50s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC50s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .
    FD2056
  • HY-148172
    L-Fd4A

    		HIV HBV Nucleoside Antimetabolite/Analog Infection
    L-Fd4A is an adenine derivative. L-Fd4A has anti-human immunodeficiency virus (HIV) (EC50=1.5 μM) and anti-hepatitis B virus (HBV) (EC50=1.7 μM) activity. L-Fd4A has low cytotoxicity .
    L-Fd4A
  • HY-P10215
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2

    		Parasite Infection
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2 (compound 40) is a potent Plasmodium subtilisin-like protease 1 (SUB1) inhibitor. SUB1-IN-1 shows IC50 values of 12 nM and 10 nM against P. vivax and P. falciparum SUB1 (Pv- and PfSUB1), respectively .
    Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
    Auristatin E
  • HY-121503
    FD44

    		Others Neurological Disease
    FD44 is a phenothiazine small molecule that inhibits the interaction between neuronal calcium sensor 1 (NCS-1) and the guanine exchange factor Ric8a, a key regulator of synapse number and neurotransmitter release probability. In the Drosophila genetic autism model of fragile X syndrome (FXS), FD44 restored normal synapse number and associative learning .
    FD44
  • HY-155996
    FD2157

    		PI3K Apoptosis Cancer
    FD2157 is a photosensitive PI3K inhibitor, with IC50s of 43 nM, 83 nM, 84 nM, 14 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ respectively. FD2157 potently inhibits cancer cell proliferation and induces cell apoptosis when exposed to 365 nm UV light .
    FD2157
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride

    LS 519-d<sub>8sub> dihydrochloride; Pirenzepin-d<sub>8sub> dihydrochloride; Gastrozepin-d<sub>8sub> dihydrochloride

    		 Isotope-Labeled Compounds mAChR Cancer
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine-d8 dihydrochloride
  • HY-G0021S
    N-Desmethylclozapine-d8

    Norclozapine-d<sub>8sub>; Desmethylclozapine-d<sub>8sub>; Normethylclozapine-d<sub>8sub>

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist .
    N-Desmethylclozapine-d8
  • HY-G0021S1
    N-Desmethylclozapine-d8 hydrochloride

    Norclozapine-d<sub>8sub> hydrochloride; Desmethylclozapine-d<sub>8sub> hydrochloride; Normethylclozapine-d<sub>8sub> hydrochloride

    		 mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine-d8 (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist .
    N-Desmethylclozapine-d8 hydrochloride
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d<sub>8sub>; Ethmozin-d<sub>8sub>; Moracizine-d<sub>8sub>

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .
    Moricizine-d8(Hydrochloride)
  • HY-50896S3
    Erlotinib-d8

    CP-358774-d<sub>8sub>; NSC 718781-d<sub>8sub>; OSI-774-d<sub>8sub>

    		 Isotope-Labeled Compounds Cancer
    Erlotinib-d8 (CP-358774-d8) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Erlotinib-d8
  • HY-15531S
    Venetoclax-d8

    ABT-199-d<sub>8sub>; GDC-0199-d<sub>8sub>; RG7601-d<sub>8sub>

    		 Bcl-2 Family Autophagy Cancer
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
    Venetoclax-d8
  • HY-14740S
    Elvitegravir-d8

    GS-9137-d<sub>8sub>; JTK-303-d<sub>8sub>; D06677-d<sub>8sub>

    		 Isotope-Labeled Compounds HIV Integrase HIV Infection
    Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d8
  • HY-17037S
    Pirenzepine-d8

    LS 519-d<sub>8sub> free base; Pirenzepin-d<sub>8sub>; Gastrozepin-d<sub>8sub>

    		 Isotope-Labeled Compounds mAChR Neurological Disease Inflammation/Immunology
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-10227S
    Bortezomib-d8

    PS-341-d<sub>8sub>; LDP-341-d<sub>8sub>; NSC 681239-d<sub>8sub>

    		 Proteasome NF-κB Apoptosis Autophagy Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .
    Bortezomib-d8
  • HY-10570S2
    Nevirapine-d8

    BI-RG 587-d<sub>8sub>; NSC 641530-d<sub>8sub>; NVP-d<sub>8sub>

    		 Isotope-Labeled Compounds Reverse Transcriptase Parasite HIV Infection Cancer
    Nevirapine-d8 (BI-RG 587-d8) is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a Ki of 270 μM .
    Nevirapine-d8
  • HY-13463BS
    Avatrombopag-d8 hydrochloride

    AKR-501-d<sub>8sub> hydrochloride; E5501-d<sub>8sub> hydrochloride; YM477-d<sub>8sub> hydrochloride

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Cardiovascular Disease
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag-d8 hydrochloride
  • HY-13011S
    Alectinib-d8

    CH5424802-d<sub>8sub>; RO5424802-d<sub>8sub>; AF802-d<sub>8sub>

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .
    Alectinib-d8
  • HY-78903A
    Monomethyl auristatin E intermediate-10

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-10 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-10
  • HY-79205
    Monomethyl auristatin E intermediate-17

    		Microtubule/Tubulin Cancer
    Monomethyl auristatin E intermediate-17 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl auristatin E intermediate-17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: